Financial toxicity-associated nivolumab dose modifications in lymphoma patients: Real-world cohort from Armenia
Lusine Harutyunyan·Astghik Voskanyan·Anna Movsisyan·Heghine Khachatryan·Diana Soghomonyan·Lusine Sahakyan·Tigran Oganesyan·Samvel Bardakhchyan·Nerses Ghahramanyan
Nivolumab is a standard-of-care treatment for relapsed/refractory (r/r) Hodgkin lymphoma (HL) and is approved for selected non-Hodgkin lymphoma (NHL) subtypes. However, high costs significantly restrict nivolumab accessibility, particularly in the developing world. This study aims to report treatment outcomes in patients with r/r HL and r/r NHL treated with standard or reduced doses of nivolumab in Armenia. A total of 16 patients diagnosed with HL and NHL between 2013 and 2023 (follow-up until M